natgillin/translations-raw huggingface dataset:
If you develop a serious rash or another of these skin symptoms, stop taking Binocrit and contact your doctor or seek medical attention immediately. 
Če se je pri vas pojavil hud izpuščaj ali kateri od teh kožnih simptomov, prenehajte z jemanjem zdravila Binocrit in se takoj posvetujte z zdravnikom ali poiščite zdravniško pomoč.
• You may be given iron supplements before and during Binocrit treatment to make it more effective. 
• Morda boste pred zdravljenjem z zdravilom Binocrit in po njem dobivali nadomestke železa, da bo zdravljenje bolj učinkovito.
If Binocrit is injected under the skin (subcutaneously), the amount injected is not normally more than one millilitre (1 mL) in a single injection. 
Če se zdravilo Binocrit injicira pod kožo (subkutano), se z eno injekcijo navadno ne injicira količina,
Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. 
Zdravilo Binocrit je indicirano pred večjimi elektivnimi ortopedskimi kirurškimi posegi pri odraslih brez pomanjkanja železa, pri katerih obstaja veliko tveganje za zaplete pri transfuziji, za zmanjšanje izpostavljenosti alogenim transfuzijam krvi.
Moreover, in patients with a baseline haemoglobin of > 13 g/dL (> 8.1 mmol/L), the possibility that epoetin alfa treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded. 
Pri bolnikih z izhodiščno koncentracijo hemoglobina > 13 g/dl (> 8,1 mmol/l) ni mogoče izključiti možnosti, da je zdravljenje z epoetinom alfa lahko povezano z zvečanim tveganjem za pooperativne trombotične žilne dogodke.
Binocrit is used in moderately anaemic adults who donate some of their blood before surgery, so that it can be given back to them during or after the operation. 
Zdravilo Binocrit se uporablja za zdravljenje zmerno anemičnih odraslih, ki pred kirurškim posegom darujejo nekaj svoje krvi, da jo lahko med kirurškim posegom ali po njem dobijo nazaj.
Binocrit can reduce the need for a blood transfusion in these patients. 
Zdravilo Binocrit lahko pri teh bolnikih zmanjša potrebo po transfuziji krvi.
• You may take Binocrit out of the refrigerator and keep it at room temperature (up to 25°C) for no longer than 3 days. 
• Zdravilo Binocrit lahko vzamete iz hladilnika in ga hranite pri sobni temperaturi (ne višji od
Your doctor will decide how Binocrit will be injected. 
Vaš zdravnik se bo odločil, kako bo injicirano zdravilo Binocrit.
Before use, leave the Binocrit syringe to stand until it reaches room temperature. 
Pred uporabo počakajte, da zdravilo Binocrit doseže sobno temperaturo.
Binocrit is not approved in the management of anaemia associated with hepatitis C. 
Zdravilo Binocrit ni odobreno za obravnavanje anemije, povezane s hepatitisom C.
Binocrit is used to treat anaemia in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma (bone marrow cancer) who may have a need for a blood transfusion. 
Zdravilo Binocrit se uporablja za zdravljenje anemije pri odraslih, če prejemate kemoterapijo za solidne tumorje, maligni limfom ali multipli mielom (rak kostnega mozga), ki morda potrebujejo transfuzijo krvi.
Binocrit is used in moderately anaemic adults about to have major orthopaedic surgery (for example hip or knee replacement operations), to reduce the potential need for blood transfusions. 
Zdravilo Binocrit se uporablja pri zmerno anemičnih odraslih, naročenih na večji ortopedski kirurški poseg (na primer menjava kolka ali kolena), da se zmanjša morebitna potreba po transfuziji krvi.
Binocrit is used to treat symptomatic anaemia caused by kidney disease: 
Zdravilo Binocrit se uporablja za zdravljenje simptomatske anemije, ki jo povzroči bolezen ledvic:
Patients should be monitored closely to ensure that the lowest approved dose of Binocrit is used to provide adequate control of anaemia and of the symptoms of anaemia. 
Bolnike je treba skrbno spremljati, da se zagotovi uporaba najmanjšega odobrenega odmerka zdravila Binocrit za doseganje ustreznega nadzora anemije in njenih simptomov.
Binocrit is prescribed to stimulate your bone marrow to produce more red blood cells. 
Zdravilo Binocrit se predpisuje za spodbujanje kostnega mozga k tvorbi rdečih krvnih celic.
How to use Binocrit 
Kako uporabljati zdravilo Binocrit
From pretreatment to presurgery, the mean increase in haemoglobin in the 600 IU/kg weekly group (1.44 g/dL) was twice than that observed in the 300 IU/kg daily group (0.73 g/dL). 
Od začetka predhodnega zdravljenja do časa pred kirurškim posegom je bilo povprečno povečanje hemoglobina v skupini s 600 i.e./kg na teden (1,44 g/dl) dvakrat večje od opaženega v skupini s 300 i.e./kg na dan (0,73 g/dl).
Epoetin alfa has been shown to stimulate red blood cell production in order to augment autologous blood collection, and to limit the decline in haemoglobin in adult patients scheduled for major elective surgery who are not expected to predeposit their complete perioperative blood needs. 
Odrasli bolniki, naročeni na kirurški poseg, ki sodelujejo v avtolognem preddonorskem programu Pokazalo se je, da epoetin alfa spodbuja nastajanje rdečih krvnih celic z namenom povečanja odvzema avtologne krvi in zmanjšanja upada hemoglobina pri odraslih bolnikih, naročenih na večji elektivni kirurški poseg, pri katerih se ne pričakuje, da bodo zbrali kri za vse njihove potrebe pri operaciji.
In repeated dose toxicological studies in dogs and rats, but not in monkeys, epoetin alfa therapy was associated with subclinical bone marrow fibrosis. 
5.3 Predklinični podatki o varnosti Nekatere toksikološke študije pri ponavljajočih odmerkih na psih in podganah, toda ne na opicah, so pokazale, da je zdravljenje z epoetinom alfa povezano s subklinično fibrozo kostnega mozga.
Binocrit is a sterile but unpreserved product and is for single use only. 
Zdravilo Binocrit je sterilno, brez dodatka konzervansa, namenjeno zgolj enkratni uporabi.
The half-life of epoetin alfa following multiple dose intravenous administration is approximately 4 hours in healthy subjects. 
Razpolovni čas epoetina alfa po intravenskem injiciranju več odmerkov je pri zdravih osebah približno 4 ure.
Instructions on how to inject Binocrit yourself 
Navodila, kako si sami injicirate zdravilo Binocrit
Some people, depending on why they need Binocrit treatment, may later learn how to inject themselves under the skin: see Instructions on how to inject Binocrit yourself at the end of the leaflet. 
Nekateri posamezniki se lahko kasneje naučijo, kako si lahko zdravilo sami injicirajo pod kožo, odvisno od tega, za kaj potrebujejo zdravilo Binocrit: glejte
Instructions on how to inject yourself with Binocrit can be found at the end of this leaflet. 
Navodila za to, kako si sami injicirate zdravilo Binocrit, lahko najdete na koncu tega navodila za uporabo zdravila.
Alternatively, Binocrit can be administered at an initial dose of 450 IU/kg subcutaneously once weekly. 
Alternativno se lahko zdravilo Binocrit daje enkrat na teden, z začetnim odmerkom 450 i.e./kg,
Where intravenous access is not readily available Binocrit may be administered subcutaneously. 
Kjer intravenski dostop ni takoj na razpolago, se zdravilo Binocrit lahko daje subkutano.
Only take one dose of Binocrit from each syringe. 
Uporabite le en odmerek zdravila Binocrit iz vsake injekcijske brizge.
In cases where there is a medical need to shorten the lead time before surgery to less than three weeks, Binocrit 300 IU/kg should be administered subcutaneously daily for 10 consecutive days prior to surgery, on the day of surgery and for four days immediately thereafter. 
Kadar moramo zaradi zdravstvenih razlogov skrajšati čas pred kirurškim posegom na manj kot tri tedne, je treba dajati 300 i.e./kg zdravila Binocrit subkutano na dan, in sicer 10 dni zapored pred kirurškim posegom, na dan kirurškega posega in še štiri dni takoj po njem.
Binocrit should be administered as a subcutaneous injection. 
Zdravilo Binocrit je treba dati v obliki subkutane injekcije.
What is in this leaflet What Binocrit is and what it is used for What you need to know before you use Binocrit How to use Binocrit Possible side effects How to store Binocrit Contents of the pack and other information What Binocrit is and what it is used for Binocrit contains the active substance epoetin alfa, a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen). 
Kaj je zdravilo Binocrit in za kaj ga uporabljamo Zdravilo Binocrit vsebuje zdravilno učinkovino epoetin alfa, beljakovino, ki spodbuja kostni mozeg k tvorbi rdečih krvnih celic, ki prenašajo hemoglobin (snov, ki prenaša kisik).
Binocrit 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 2,000 IU/1 mL solution for injection in a pre-filled syringe Binocrit 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Binocrit 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Binocrit 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Binocrit 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Binocrit 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Binocrit 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Binocrit 10,000 IU/1 mL solution for injection in a pre-filled syringe Binocrit 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Binocrit 40,000 IU/1 mL solution for injection in a pre-filled syringe 
Binocrit 1.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 2.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 3.000 i.e./0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 4.000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 5.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 6.000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 10.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 20.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 40.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit contains sodium 
Zdravilo Binocrit vsebuje natrij
Stop using Binocrit if you develop these symptoms and contact your doctor or seek medical attention immediately. 
Če se pri vas pojavijo ti simptomi, prenehajte uporabljati zdravilo Binocrit in se takoj posvetujte z zdravnikom ali poiščite zdravniško pomoč.
In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Binocrit by the intravenous route is preferable. 
Pri bolnikih s kronično ledvično odpovedjo, pri katerih je intravenski dostop rutinsko na razpolago (bolniki na hemodializi), je zaželeno intravensko dajanje zdravila Binocrit.
Binocrit contains less than 1 mmol sodium (23 mg) per dose that is to say essentially “sodium free”. 
Zdravilo Binocrit vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni „brez natrija“.
Package leaflet: Information for the patient Binocrit 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 2,000 IU/1 mL solution for injection in a pre-filled syringe Binocrit 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Binocrit 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Binocrit 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Binocrit 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Binocrit 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Binocrit 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Binocrit 10,000 IU/1 mL solution for injection in a pre-filled syringe Binocrit 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Binocrit 40,000 IU/1 mL solution for injection in a pre-filled syringe Epoetin alfa Read all of this leaflet carefully before you start using this medicine because it contains important information for you. 
NAVODILO ZA UPORABO Binocrit 1.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 2.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 3.000 i.e./0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 4.000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 5.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 6.000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 10.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 20.000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Binocrit 40.000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi epoetin alfa
If you can't take medicines that prevent blood clotting, you must not have Binocrit. 
Če ne smete jemati zdravil za preprečevanje nastanka krvnih strdkov,
Binocrit should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)). 
Zdravilo Binocrit se daje bolnikom s simptomatsko anemijo (npr. koncentracijo hemoglobina ≤ 10 g/dl (6,2 mmol/l)).
What you need to know before you use Binocrit 
Kaj morate vedeti, preden boste uporabili zdravilo Binocrit Ne uporabljajte zdravila Binocrit:
Only one dose of Binocrit from each syringe should be taken. 
Odmeri se lahko le en odmerek zdravila Binocrit iz vsake brizge.
Contents of the pack and other information 
Shranjevanje zdravila Binocrit Vsebina pakiranja in dodatne informacije
If the haemoglobin concentration is increasing by more than 2 g/dL (1.25 mmol/L) per month, or if the haemoglobin concentration level exceeds 12 g/dL (7.5 mmol/L), reduce the Binocrit dose by about 25 to 50%. 
Če se koncentracija hemoglobina zveča za več kot 2 g/dl (1,25 mmol/l) na mesec, ali če raven koncentracije hemoglobina preseže 12 g/dl (7,5 mmol/l), zmanjšajte odmerek zdravila Binocrit za približno 25 do 50 %.
- All contraindications associated with autologous blood predonation programmes should be respected in patients being supplemented with Binocrit. 
- Pri bolnikih, ki dobivajo zdravilo Binocrit, je treba upoštevati vse kontraindikacije, povezane s preddonorskimi programi avtolognega zbiranja krvi.
A major cardiovascular event (death, myocardial infarction, stroke or hospitalisation for congestive heart failure) occurred among 125 (18%) of the 715 patients in the higher haemoglobin group compared to 97 (14%) among the 717 patients in the lower haemoglobin group (hazard ratio [HR] 1.3, 95% CI: 1.0, 1.7, p = 0.03). 
715 bolnikov v skupini z večjim hemoglobinom v primerjavi s 97 (14 %) od 717 bolnikov v skupini z manjšim hemoglobinom (razmerje tveganja [RT] 1,3, 95-% IZ: 1,0; 1,7, p = 0,03).
Some patients with more extended dosing intervals (greater than once weekly) of epoetin alfa may not maintain adequate haemoglobin levels (see section 5.1) and may require an increase in epoetin alfa dose. 
morda ne bo mogoče vzdrževati ustrezne ravni hemoglobina (glejte poglavje 5.1) in bo treba odmerek epoetina alfa povečati.
The starting dose is 50 IU/kg, 2 times per week. 
Začetni odmerek je 50 i.e./kg, 2-krat na teden.
Take special care with Binocrit: 
Pri uporabi zdravila Binocrit bodite posebej previdni:
What Binocrit contains - The active substance is: epoetin alfa (for quantity see the table below). 
- Učinkovina: epoetin alfa (količine so razvidne iz spodnje preglednice).
If the haemoglobin level reaches 15 g/dL (9.38 mmol/L), or higher, during the preoperative period, administration of Binocrit should be stopped and further dosages should not be administered. 
Če v obdobju pred kirurškim posegom raven hemoglobina doseže 15 g/dl (9,38 mmol/l) ali več, je treba zdravljenje z zdravilom Binocrit prekiniti.
What Binocrit looks like and contents of the pack Binocrit is presented as a clear, colourless solution for injection in a pre-filled syringe. 
Zdravilo Binocrit je bistra, brezbarvna raztopina za injiciranje v napolnjeni injekcijski brizgi.
Treatment of adult patients with chemotherapy-induced anaemia 
Zdravljenje odraslih bolnikov z anemijo, ki je posledica kemoterapije
If the haemoglobin is rising by more than 2 g/dL (1.25 mmol/L) per month, or if the sustained haemoglobin exceeds 12 g/dL (7.5 mmol/L) reduce the Binocrit dose by 25%. 
Če se hemoglobin zviša za več kot 2 g/dl (1,25 mmol/l) na mesec, ali če stalna vrednost hemoglobina preseže 12 g/dl (7,5 mmol/l), zmanjšajte odmerek zdravila Binocrit za 25 %.
This is characterised by a sustained decrease in haemoglobin despite an increase in epoetin alfa dosage (see section 4.8). 
Zanjo je značilno trajno zmanjšanje koncentracije hemoglobina kljub povečanju odmerka epoetina alfa
“Instructions on how to inject Binocrit yourself” can be found at the end of the package leaflet. 
„Navodila za samoinjiciranje zdravila Binocrit“ lahko najdemo na koncu navodila za uporabo.
Tell your doctor or nurse immediately if you think too much Binocrit has been injected. 
Če ste uporabili večji odmerek zdravila Binocrit, kot bi smeli Takoj obvestite svojega zdravnika ali medicinsko sestro, če mislite, da ste injicirali prevelik odmerek zdravila Binocrit.
Do not shake Binocrit syringes. 
Injekcijskih brizg z zdravilom Binocrit ne stresajte.
Only take one dose of Binocrit from each syringe discarding unwanted solution before injection. 
Iz vsake brizge odvzemite samo en odmerek zdravila Binocrit in pred injiciranjem zavrzite preostalo raztopino.
If you are a cancer patient be aware that products that stimulate red blood cell production (like Binocrit) may act as a growth factor and therefore in theory may affect the progression of your cancer. 
(kot je zdravilo Binocrit), delujejo kot rastni faktor in s tem teoretično vplivajo na napredovanje raka.
No evidence exists that indicates that treatment with epoetin alfa alters the metabolism of other medicinal products. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Ni dokazov, ki kažejo, da zdravljenje z epoetinom alfa vpliva na metabolizem drugih zdravil.
Binocrit should be administered by the intravenous route. 
Zdravilo Binocrit je treba dati intravensko.
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). 
Za bolnike z rakom, ki so prejemali kemoterapijo, je bilo razmerje tveganja celokupnega preživetja 1,04 (95 % IZ: 0,97; 1,11; 38 preskušanj in 10.441 bolnikov).
Baseline Characteristics for Subjects with sEPO < 200 mU/mL at Screening 
Izhodiščne značilnosti oseb s sEPO < 200 me./ml ob presejanju Randomizirani
If the haemoglobin concentration level exceeds 13 g/dL (8.1 mmol/L), discontinue therapy until it falls below 12 g/dL (7.5 mmol/L) and then reinitiate Binocrit therapy at a dose 25% below the previous dose. 
Če raven koncentracije hemoglobina preseže 13 g/dl (8,1 mmol/l), je treba zdravljenje prekiniti, dokler se ne zmanjša pod 12 g/dl (7,5 mmol/l), in nato zdravljenje z zdravilom Binocrit začeti znova z odmerkom, ki je za približno 25 % manjši od predhodnega.
If the haemoglobin exceeds 13 g/dL (8.1 mmol/L), discontinue therapy until it falls below 12 g/dL (7.5 mmol/L) and then reinstitute Binocrit therapy at a dose 25% below the previous dose. 
Če hemoglobin preseže 13 g/dl (8,1 mmol/l), je treba zdravljenje prekiniti, dokler se ne zmanjša pod 12 g/dl (7,5 mmol/l), in nato zdravljenje nadaljevati z zdravilom Binocrit z odmerkom, ki je 25 % manjši od prejšnjega odmerka.
How to store Binocrit 
Shranjevanje zdravila Binocrit
Store and transport refrigerated (2°C-8°C). 
POSEBNA NAVODILA ZA SHRANJEVANJE Zdravilo shranjujte in prevažajte na hladnem (2 °C - 8 °C).
INFORMATION IN BRAILLE Binocrit 8,000 IU/0.8 mL 
PODATKI V BRAILLOVI PISAVI Binocrit 8.000 i.e./0,8 ml
Binocrit 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Each syringe contains 0.8 mL of solution for injection. 
Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,8 ml raztopine za injiciranje.
Binocrit should be administered in order to increase haemoglobin to not greater than 12 g/dL (7.5 mmol/L). 
Zdravilo Binocrit se daje z namenom zvišati hemoglobin na raven do 12 g/dl (7,5 mmol/l).
INFORMATION IN BRAILLE Binocrit 30,000 IU/0.75 mL 
PODATKI V BRAILLOVI PISAVI Binocrit 30.000 i.e./0,75 ml
INFORMATION IN BRAILLE Binocrit 7,000 IU/0.7 mL 
PODATKI V BRAILLOVI PISAVI Binocrit 7.000 i.e./0,7 ml
INFORMATION IN BRAILLE Binocrit 9,000 IU/0.9 mL 
PODATKI V BRAILLOVI PISAVI Binocrit 9.000 i.e./0,9 ml
Binocrit 8,000 IU/0.8 mL solution for injection in a pre-filled syringe 
Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Each syringe contains 0.7 mL of solution for injection. 
Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,7 ml raztopine za injiciranje.
Binocrit 8,000 IU/0.8 mL solution for injection in a pre-filled syringe EU/1/07/410/013 
Binocrit 8.000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/410/013
Binocrit 9,000 IU/0.9 mL solution for injection in a pre-filled syringe 
Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 7,000 IU/0.7 mL solution for injection in a pre-filled syringe 
Binocrit 7.000 i.e./0,7 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Binocrit 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Each syringe contains 0.9 mL of solution for injection. 
Binocrit 9.000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,9 ml raztopine za injiciranje.
The use of Binocrit in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident. 
Pri bolnikih, naročenih na večji elektivni ortopedski kirurški poseg in ki niso vključeni v program avtolognega zbiranja krvi, je uporaba zdravila Binocrit kontraindicirana, če imajo hudo koronarno,
INFORMATION IN BRAILLE Binocrit 6,000 IU/0.6 mL 
PODATKI V BRAILLOVI PISAVI Binocrit 6.000 i.e./0,6 ml
INFORMATION IN BRAILLE Binocrit 40,000 IU/1 mL 
PODATKI V BRAILLOVI PISAVI Binocrit 40.000 i.e./1 ml
Binocrit 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Each syringe contains 0.75 mL of solution for injection. 
Binocrit 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Ena napolnjena injekcijska brizga vsebuje 0,75 ml raztopine za injiciranje.